Serotonin Transporter Dynamics in Multiple System Atrophy: Insights from 123I-FP-CIT SPECT Imaging
Objective: We aimed to visualize a serotonin transporter (SERT) based on 123I-FP-CIT SPECT, and assessing the binding distribution characteristics of the brainstems between patients with…Prospective Study of Gait and Multimodal MRI Biomarkers for Multiple System Atrophy
Objective: We aimed to develop new multimodal biomarkers allowing objective monitoring of early MSA progression to improve outcome definition for future neuroprotective trials. Background: MSA…Association Between Clinical Progression in Multiple System Atrophy and Brain Volume Changes Evaluated via Deep Learning Segmentation
Objective: Assess brain volume changes in patients with multiple system atrophy (MSA) over one year. Background: Identifying disease progression biomarkers is crucial for advancing MSA…Heterogeneity of multiple system atrophy with an analysis of the clinical case
Objective: Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative disease clinically characterized by various combinations of Parkinsonism with resistance to levodopa, cerebellar, autonomic, and…Posterior Fossa Arachnoid Cysts In Two Patients With Suspected Multiple System Atrophy – Cerebellar Type
Objective: To describe two patients with posterior fossa arachnoid cysts later diagnosed with suspected multiple system atrophy – cerebellar type (MSA-C). Background: The diagnosis of…Nigral Neuroinflammation and Dopaminergic Neurons in PD, MSA and PSP: A Comparative Clinicopathological Study
Objective: To investigate nigral neuroinflammatory markers and dopaminergic neuron counts in parkinsonian disorders, comparing their profiles across conditions. Background: In degenerative parkinsonian disorders, the primary…Peripheral inflammation severity in differential diagnosis of progressive supranuclear palsy and multiple system atrophy – usefulness of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and neutrophil-to-high-density lipoprotein-cholesterol ratio
Objective: Assessment of the possible differences in peripheral inflammation severity between progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) with the use of three…A group of patients with multiple system atrophy (MSA) exhibit cardiac sympathetic dysfunction to the same extent as Parkinson’s disease (PD).
Objective: Although there are cases of multiple system atrophy (MSA) with decreased MIBG, there has not been sufficient investigation into the proportion. Thus, we retrospectively…Blood NfL can track progression in multiple system atrophy
Objective: To validate the role of NfL for disease progression, severity and subject trial selection in MSA. Neurofilament light (NfL) was explored in this regard though…Preliminary evidence for evolution of myoinositol and N-acteylaspartate as biomarkers of disease severity in early-stage multiple system atrophy
Objective: To quantify the longitudinal evolution of metabolic indicators of gliosis and neuronal integrity in patients with multiple system atrophy (MSA) over one year. Background:…
- 1
- 2
- 3
- …
- 7
- Next Page »